Pharmacology, toxicology and clinical safety of glycopyrrolate

  title={Pharmacology, toxicology and clinical safety of glycopyrrolate},
  author={Monika Chabicovsky and Swantje Winkler and Michael Soeberdt and Ana Kilic and Clarissa Masur and Christoph Abels},
  journal={Toxicology and Applied Pharmacology},

Figures and Tables from this paper

Inhaled Medicines: Past, Present, and Future

A review of the key aspects of approved orally inhaled drug products for a variety of respiratory diseases and for systemic administration should be helpful in making judicious decisions about the development of new or improved inhaled drugs.

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis

These studies indicate limited absorption of GT compared to oral glycopyrrolate and a low risk of anticholinergic adverse events with proper GT administration when following instructions for use.

Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience

This study demonstrates the efficacy of a compounded glycopyrrolate syrup on drooling severity, frequency and ensures a better QoL in patients and their caregivers.

Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin

The main variables associated with treatment adherence by patients receiving OGly, for whom previous treatment with OOx had failed, were identified and provided valuable insights into the outcomes achieved when OGly is used to treat hyperhidrosis.

Topical anticholinergic medications for primary hyperhidrosis: A protocol for systematic review and meta-analysis

Evaluating systemic and topical safety and tolerability of topical application of anticholinergics for PHH and analysis of evidence for the efficacy and toleration is limited.

Drug–Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications

This review searched articles published until 30 August 2021, and described both pharmacokinetic and pharmacodynamic DDIs in patients with vestibular disorders, focusing the interest on their clinical implications and on risk management strategies.


Based on the available evidences, topical glycopyrrolate, oxybutynin and botulinum toxin A should be considered as first-line therapies of facial hyperhidrosis due to their efficacy and safety.

Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics

This review shows that while available safety data thus far are limited, emerging topical anticholinergics pose minimal known human risks.

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Recent progress in synthetic drug development of compounds targeting neuroendocrine signalling in the skin and its appendages to treat skin diseases such as atopic dermatitis, psoriasis, acne, alopecia areata and hyperhidrosis is focused on.

Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis

Mydriasis associated with topical GT seems to be a consequence of local exposure rather than systemic toxicity, and soft contact lens wear and poor postapplication hand hygiene seem to be associated with mydriasis in GT use.

Pharmacokinetics and related pharmacodynamics of anticholinergic drugs

The pharmacokinetics and some pharmacodynamic properties of atropine, glycopyrrolate and scopolamine are reviewed and the differences in clinical effects are not very prominent in healthy patients.

Glycopyrrolate for chronic drooling in children.

A condensed format for reporting toxicologic data--results of studies on glycopyrrolate.


Glycopyrrolate is described, a white crystalline solid of two diastereoisomeric racemates, which was selected for an extensive pharmacological evaluation on the basis of the results of the earlier study.

Anticholinergics for Overactive Bladder Therapy: Central Nervous System Effects

The physicochemical and pharmacokinetic properties of OAB antimuscarinics that affect their propensity to cause adverse CNS effects are discussed, as observed in phase III clinical trials and in specific investigations on cognitive function and sleep architecture.

Glycopyrrolate Oral Solution

In general, glycopyrrolate oral solution was well tolerated in clinical trials, and the majority of adverse events were within expectations as characteristic anticholinergic outcomes.

Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects

Comparison of systemic exposure to glycopyrronium in Chinese versus the non-Chinese population did not indicate clinically relevant ethnic differences and the pharmacokinetic steady state was reached after 5 days of daily dosing.

Safety of available and emerging drug therapies for hyperhidrosis

Efficacy and safety data on aluminum salts, anticholinergic drugs for topical or systemic application, and on intradermal botulinum toxin injections used to treat hyperhidrosis are critically evaluated, including data from clinical trials with focus on possible side effects and long-term complications in dispute.

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

The overall safety profile of glycopyrronium was similar to its comparators indicating no increase in the overall risk for any of the investigated safety end points.

Comparative Penetration of Glycopyrrolate and Atropine across the Blood—Brain and Placental Barriers in Anesthetized Dogs

It is shown that glycopyrrolate is a selective peripheral anticholinergic agent, in that it is more resistant than atropine to penetration across the blood—brain and placental barriers.